LAURUSLABS vs MANGALAM: Stock Comparison

Laurus Labs Limited vs Mangalam Drugs And Organics Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Laurus Labs Limited is the larger company by market capitalisation. Laurus Labs Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Laurus Labs Limited and Mangalam Drugs And Organics Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LAURUSLABS is more favourable on 11 of 11 scored metrics and MANGALAM on 0These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LAURUSLABS is the larger company
₹85,251 Cr vs ₹43 Cr
EPS
LAURUSLABS has higher earnings per share
₹16.46 vs ₹-28.05
Dividend Yield
LAURUSLABS has a higher dividend yield
0.19% vs 0%
Revenue Growth (TTM YoY)
LAURUSLABS has faster revenue growth
5.3% vs -7.5%
EPS Growth (TTM YoY)
LAURUSLABS has faster EPS growth
19.4% vs 0%
Qtr Sales Growth
LAURUSLABS has stronger quarterly sales growth
5.31% vs -7.54%
Qtr Profit Growth
LAURUSLABS has stronger quarterly profit growth
19.5% vs -22,467%
ROE
LAURUSLABS has a higher ROE
18.3% vs -35.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLAURUSLABSMANGALAM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLAURUSLABSMANGALAM
Live Price₹1,580.7₹27.08
Day Change-0.78%-0.66%
Volume9.95 L25,356
52-Week High₹1,600.1₹95
52-Week Low₹810.05₹22.8
Distance from 52W High-1.21%-71.49%

Valuation

MetricLAURUSLABSMANGALAM
Market Cap₹85,251 Cr₹43 Cr
P/E Ratio96.78x
P/B Ratio16.22x
EPS₹16.46₹-28.05
Book Value₹98.16₹65.12
Dividend Yield0.19%0%

Growth

MetricLAURUSLABSMANGALAM
Revenue Growth (TTM YoY)5.3%-7.5%
EPS Growth (TTM YoY)19.4%0%
Qtr Sales Growth5.31%-7.54%
Qtr Profit Growth19.5%-22,467%

Profitability & Leverage

MetricLAURUSLABSMANGALAM
ROE18.3%-35.2%
ROCE17.8%-14.3%
Net Margin13.76%-19.13%
Operating Margin26.2%-6.42%
Debt to Equity0.48x1.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLAURUSLABSMANGALAM
Promoter Holding27.49%35.65%
FII Holding25.82% 0.7 pp0.11% 0.21 pp
DII Holding13.97% 1.54 pp0%
Public Holding32.71% 0.85 pp64.24% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Laurus Labs Limited and Mangalam Drugs And Organics Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.